2022
NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies
Marks A, Antaya R, Balsamo L, Cardinale K, Cheron R, Frumberg D, Gentile V, Habib L, Puthenpura V, Zhang H. NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies. Neuro-Oncology 2022, 24: i129-i129. PMCID: PMC9165028, DOI: 10.1093/neuonc/noac079.469.Peer-Reviewed Original ResearchTuberous sclerosisPediatric patients 2 yearsYale-New Haven Children's HospitalInoperable plexiform neurofibromasPatients 2 yearsOwn side effectsYears of ageNeurofibromatosis type 1Multidisciplinary clinicNeurocutaneous syndromeChildren's HospitalPlexiform neurofibromaNeuro-oncologySide effectsSubspecialty consultationClinicType 1Young adultsSclerosisSyndromeHospitalTherapyAgeTreatmentClinical reasoning
2016
Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ disease
Puthenpura V, Desai K, Bauer A, Marshall I. Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ disease. International Journal Of Pediatric Endocrinology 2016, 2016: 16. PMID: 27605984, PMCID: PMC5013617, DOI: 10.1186/s13633-016-0034-6.Peer-Reviewed Original ResearchOlder patientsMMI therapySide effectsMethimazole-induced agranulocytosisMonths of treatmentRare side effectSerious side effectsDose-dependent mannerMethimazole therapyPediatric GravesCase presentationWeDisease populationUnusual casePatientsInconclusive dataTherapyAgranulocytosisDependent mannerTypical timelineMonthsGravesIncidenceConclusionsThisDisease